Pulsesight reports positive phase 1 data for PST‑611 in dry AMD
11th May 2026 Uncategorised 0
Early safety and efficacy signals support move into repeat‑dose phase 2a trial

More: Pulsesight reports positive phase 1 data for PST‑611 in dry AMD
Source: News
